Oncolytics Biotech Pelareorep Shows Durable Responses in RAS-Mutant Colorectal Cancer Trial

Key Takeaways

• Pelareorep demonstrates meaningful and sustained clinical benefit in RAS-mutant, microsatellite-stable colorectal cancer patients
• New durability data strengthens the case for pelareorep as a potential second-line treatment option for difficult-to-treat patient population
• Results support continued development of the systemically delivered immunotherapy that activates innate immune-sensing pathways

---

SAN DIEGO - Oncolytics Biotech Inc. (Nasdaq: ONCY) announced promising new durability data for its investigational immunotherapy pelareorep in metastatic colorectal cancer (mCRC) patients on May 4, 2026. The clinical-stage biotechnology company reported sustained clinical benefit in patients with RAS-mutant, microsatellite-stable (MSS) disease, a particularly challenging-to-treat cancer subtype.

Breakthrough in Hard-to-Treat Cancer Population

The new data represents a significant development for patients with RAS-mutant MSS colorectal cancer, who have historically had limited treatment options in the second-line setting. RAS mutations occur in approximately 40-50% of colorectal cancer cases and are associated with resistance to certain targeted therapies.

Pelareorep is a systemically delivered immunotherapy that works by activating innate immune-sensing pathways, potentially helping the body’s immune system recognize and attack cancer cells more effectively. This mechanism of action differs from traditional chemotherapy approaches and represents a novel approach to treating colorectal cancer.

Market Impact and Clinical Significance

Colorectal cancer remains the third most common cancer worldwide, with metastatic disease carrying a poor prognosis. The MSS subtype, which represents about 85% of colorectal cancers, has been particularly resistant to immunotherapy approaches that have shown success in other cancer types.

The durability aspect of the response data is particularly noteworthy, as sustained clinical benefit is a key metric that regulators and oncologists evaluate when assessing new cancer treatments. Durable responses suggest that pelareorep may provide long-term benefit rather than just temporary tumor control.

Next Steps in Development

Oncolytics Biotech continues to advance pelareorep through clinical development, with these positive durability results potentially supporting future regulatory discussions. The company’s focus on the second-line setting addresses a significant unmet medical need, as patients who progress after first-line therapy have fewer effective treatment options available.

---

Frequently Asked Questions

What does this mean for colorectal cancer patients?

The durable responses suggest pelareorep could become a new treatment option for patients with RAS-mutant MSS colorectal cancer who have limited second-line therapy choices, potentially extending survival and improving quality of life.

When will pelareorep be available to patients?

Pelareorep is still in clinical trials and not yet approved. The timeline for potential FDA approval depends on completing additional clinical studies and regulatory review, which typically takes several years.

How does pelareorep differ from current colorectal cancer treatments?

Unlike traditional chemotherapy, pelareorep is an immunotherapy that activates the body’s innate immune system to fight cancer cells, potentially offering a different mechanism of action with distinct side effect profile.